CRIS - Curis, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.7100
-0.0200 (-1.16%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.7300
Open1.7500
Bid1.6700 x 1200
Ask1.7400 x 800
Day's Range1.6700 - 1.7699
52 Week Range0.9900 - 2.9000
Volume94,040
Avg. Volume269,635
Market Cap56.777M
Beta (5Y Monthly)2.41
PE Ratio (TTM)N/A
EPS (TTM)-0.8890
Earnings DateMar 23, 2020 - Mar 29, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
  • PR Newswire

    Curis® and DarwinHealth Announce Scientific Collaboration to Characterize Biomarkers and Tumor Subtype Alignments for Fimepinostat in DLBCL and Solid Malignancies

    Curis, Inc (NASDAQ: CRIS) and DarwinHealth, Inc. today announced a multi-year scientific research collaboration to use quantitative, systems biology-based algorithms, CLIA-approved technologies, and novel, validated approaches focused on Master Regulator (MR) proteins and tumor checkpoints to: (a) better understand and articulate the role of MYC in fimepinostat's mechanism of action; and (b) explore additional potential novel biomarkers that may help patient selection in hematologic and solid tumors clinical studies.

  • Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    PR Newswire

    Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on January 2, 2020, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 140,000 shares of Curis common stock to two new employees, with a grant date of January 2, 2020 (the "Q1 2020 Inducement Grants").

  • Curis Announces Option and License Agreement with ImmuNext for the Development and Commercialization of Anti-VISTA Antibodies
    PR Newswire

    Curis Announces Option and License Agreement with ImmuNext for the Development and Commercialization of Anti-VISTA Antibodies

    Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into an option and license agreement to acquire exclusive, worldwide rights from ImmuNext Inc. (ImmuNext) to develop and commercialize anti-VISTA antibodies for the treatment of cancer, including ImmuNext's lead compound, CI-8993 (formerly JNJ-61610588). CI-8993 is a clinical-stage monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation (VISTA) signaling pathway.

  • Should You Buy Curis, Inc. (CRIS)?
    Insider Monkey

    Should You Buy Curis, Inc. (CRIS)?

    We can judge whether Curis, Inc. (NASDAQ:CRIS) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabilities working for us than to follow their lead into their best ideas. […]

  • The Curis (NASDAQ:CRIS) Share Price Is Up 103% And Shareholders Are Boasting About It
    Simply Wall St.

    The Curis (NASDAQ:CRIS) Share Price Is Up 103% And Shareholders Are Boasting About It

    Some Curis, Inc. (NASDAQ:CRIS) shareholders are probably rather concerned to see the share price fall 37% over the...

  • Curis Provides First-Ever Demonstration that Targeting IRAK4 in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Results in Anti-Cancer Activity in Ongoing Phase 1 Study
    PR Newswire

    Curis Provides First-Ever Demonstration that Targeting IRAK4 in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Results in Anti-Cancer Activity in Ongoing Phase 1 Study

    Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced updated preliminary data from its ongoing Phase 1 dose escalation study of CA-4948, an IRAK4 kinase inhibitor, for the treatment of patients with relapsed or refractory (R/R) non-Hodgkin's lymphoma (NHL), including patients with diffuse large B-cell lymphoma (DLBCL), Waldenström's macroglobulinemia (WM) and oncogenic MYD88 mutations.

  • Thomson Reuters StreetEvents

    Edited Transcript of CRIS earnings conference call or presentation 5-Nov-19 1:30pm GMT

    Q3 2019 Curis Inc Earnings Call

  • Curis Abstracts for Fimepinostat and CA-4948 Accepted for Presentation at the 61st Annual Meeting of the American Society of Hematology
    PR Newswire

    Curis Abstracts for Fimepinostat and CA-4948 Accepted for Presentation at the 61st Annual Meeting of the American Society of Hematology

    LEXINGTON, Mass. , Nov. 6, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that ...

  • Curis Reports Third Quarter 2019 Financial Results
    PR Newswire

    Curis Reports Third Quarter 2019 Financial Results

    LEXINGTON, Mass., Nov. 5, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the third quarter ended September 30, 2019. "We are pleased by the safety and tolerability profile of CA-170 in our Phase 1 study and continue to believe VISTA is an important and scientifically-validated target. Curis is evaluating fimepinostat (a MYC suppressor) with venetoclax (a BCL-2 inhibitor) combination regimen in an ongoing Phase 1 study in diffuse large B-cell lymphoma (DLBCL), including patients with double-hit/double-expressor (DH/DE) lymphoma.

  • /U P D A T E D -- Curis, Inc./
    PR Newswire

    /U P D A T E D -- Curis, Inc./

    In a release issued under the same headline on October 29th by Curis, Inc., please note that in the first and second paragraphs of the release, financial results will be reported before Nasdaq market open, not after market close. LEXINGTON, Mass., Oct. 29, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its third quarter financial results on Tuesday, November 5, 2019, before the open of US markets. A replay of the financial results conference call will be available on the Curis website shortly after completion of the call.

  • Curis to Release Third Quarter Financial Results and Hold Conference Call on November 5, 2019
    PR Newswire

    Curis to Release Third Quarter Financial Results and Hold Conference Call on November 5, 2019

    LEXINGTON, Mass., Oct. 29, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its third quarter financial results on Tuesday, November 5, 2019, after the close of US markets. Management will host a conference call on the same day at 4:30 p.m. ET. To access the live conference call, please dial (888) 346-6389 from the United States or (412) 317-5252 from other locations, shortly before 4:30 p.m. ET.

  • PR Newswire

    Curis to Present at Cantor Fitzgerald Global Healthcare Conference

    LEXINGTON, Mass., Sept. 26, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, Chief Executive Officer of Curis, will present at the Cantor Fitzgerald Global Healthcare Conference on Thursday, October 3, 2019 at 3:00 p.m. ET in New York, NY. Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, including fimepinostat, which is being investigated in clinical studies in patients with DLBCL and solid tumors.

  • We Think Curis (NASDAQ:CRIS) Needs To Drive Business Growth Carefully
    Simply Wall St.

    We Think Curis (NASDAQ:CRIS) Needs To Drive Business Growth Carefully

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

  • PR Newswire

    Curis Announces Promotion of Bill Steinkrauss to Chief Financial Officer

    LEXINGTON, Mass., Sept. 12, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the promotion of Bill Steinkrauss to Chief Financial Officer. Mr. Steinkrauss joined Curis in August 2016 and most recently served as Treasurer and Vice President of Finance. "Since joining Curis, Bill has played a critical role in the growth and success of our Company, demonstrating his expertise in business and financial strategy.

  • PR Newswire

    Curis Reports Second Quarter 2019 Financial Results

    LEXINGTON, Mass., Aug. 6, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the second quarter ended June 30, 2019. "Today, we are excited to announce initial data from our ongoing Phase 1 study of CA-4948 in patients with non-Hodgkin lymphoma, demonstrating anti-cancer activity for CA-4948 with tumor reduction observed in multiple patients across multiple dose levels," said James Dentzer, President and Chief Executive Officer of Curis. "I am very pleased with the initial data we are seeing in our ongoing Phase 1 trial of CA-4948," said Robert Martell, Head of R&D of Curis.  "As we increase dosing, we have observed continued evidence of pharmacodynamic target inhibition with dose-proportional increases in pharmacokinetic exposure.

  • Curis to Release Second Quarter Financial Results and Hold Conference Call on August 6, 2019
    PR Newswire

    Curis to Release Second Quarter Financial Results and Hold Conference Call on August 6, 2019

    LEXINGTON, Mass., July 30, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its second quarter financial results on Tuesday, August 6, 2019, after the close of US markets. Management will host a conference call on the same day at 4:30 p.m. ET. To access the live conference call, please dial (888) 346-6389 from the United States or (412) 317-5252 from other locations, shortly before 4:30 p.m. ET.

  • Could Curis, Inc.'s (NASDAQ:CRIS) Investor Composition Influence The Stock Price?
    Simply Wall St.

    Could Curis, Inc.'s (NASDAQ:CRIS) Investor Composition Influence The Stock Price?

    If you want to know who really controls Curis, Inc. (NASDAQ:CRIS), then you'll have to look at the makeup of its share...

  • Curis Highlights Publication in Nature Cell Biology Identifying Cancer-Causing Form of IRAK4 in Patients with AML and MDS
    PR Newswire

    Curis Highlights Publication in Nature Cell Biology Identifying Cancer-Causing Form of IRAK4 in Patients with AML and MDS

    LEXINGTON, Mass., June 12, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today highlighted a publication titled "U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies" in Nature Cell Biology.1 The study findings demonstrate that a cancer-causing splicing variant of IRAK4 (IRAK4-L) is dominant in the majority of cases of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Additionally, specific mutations of the U2AF1 splicing factor induce IRAK4-L, which has potential therapeutic targetability by CA-4948, the Company's small molecule inhibitor of IRAK4.

  • Thomson Reuters StreetEvents

    Edited Transcript of CRIS earnings conference call or presentation 14-May-19 8:30pm GMT

    Q1 2019 Curis Inc Earnings Call

  • Associated Press

    Curis: 1Q Earnings Snapshot

    The Lexington, Massachusetts-based company said it had a loss of 30 cents per share. Losses, adjusted to extinguish debt, came to 19 cents per share. The drug developer posted revenue of $2.1 million in ...

  • Curis Reports First Quarter 2019 Financial Results
    PR Newswire

    Curis Reports First Quarter 2019 Financial Results

    LEXINGTON, Mass., May 14, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the first quarter ended March 31, 2019.

  • PR Newswire

    Curis to Release First Quarter Financial Results and Hold Conference Call on May 14, 2019

    LEXINGTON, Mass., May 7, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its first quarter financial results on Tuesday, May 14, 2019, after the close of US markets. Management will host a conference call on the same day at 4:30 p.m. ET. To access the live conference call, please dial (888) 346-6389 from the United States or (412) 317-5252 from other locations, shortly before 4:30 p.m. ET.

  • PR Newswire

    Curis Completes Mesothelioma Enrollment in CA-170 Study

    LEXINGTON, Mass., May 6, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Phase 1 study of CA-170 has reached its target enrollment of mesothelioma patients. Today's announcement is a direct result of those efforts," said James Dentzer, President & CEO of Curis. CA-170 is an orally available, dual inhibitor of VISTA and PDL1, which the company believes could provide benefit in tumors with high levels of VISTA expression.

  • Some Curis (NASDAQ:CRIS) Shareholders Have Taken A Painful 83% Share Price Drop
    Simply Wall St.

    Some Curis (NASDAQ:CRIS) Shareholders Have Taken A Painful 83% Share Price Drop

    It is doubtless a positive to see that the Curis, Inc. (NASDAQ:CRIS) share price has gained some 40% in the last three months. But spare a thought for the long term holders, who have held the stock as it bled value over the la...